REQUEST A DEMO
Total
USD $0.00
Search more companies

Sterling Drug (Malaya) S/B (Malaysia)

Main Activities: Medicinal and Botanical Manufacturing
Full name: Sterling Drug (Malaya) S/B Profile Updated: February 05, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

Sterling Drug (Malaya) S/B is an enterprise in Malaysia, with the main office in Ampang. It operates in the Medicinal and Botanical Manufacturing industry. The enterprise was incorporated on March 03, 1962. In 2023, the company reported a net sales revenue increase of 33.78%. There was a total growth of 70.52% in Sterling Drug (Malaya) S/B’s total assets over the same period. The net profit margin of Sterling Drug (Malaya) S/B decreased by 1.39% in 2023.

Headquarters
Lot 89 Jalan Enggang, Ampang/Hulu Kelang Industrial Estate
Ampang; Selangor; Postal Code: 68000

Contact Details: Purchase the Sterling Drug (Malaya) S/B report to view the information.

Basic Information
Outstanding Shares:
Purchase the Sterling Drug (Malaya) S/B report to view the information.
Registered Capital:
Purchase the Sterling Drug (Malaya) S/B report to view the information.
Financial Auditors:
Purchase the Sterling Drug (Malaya) S/B report to view the information.
Incorporation Date:
March 03, 1962
Key Executives
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Secretary
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Sterling Drug (Malaya) S/B report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency MYR. Absolute financial data is included in the purchased report.
Net sales revenue
33.78%
Total operating revenue
33.78%
Operating profit (EBIT)
-34.58%
EBITDA
-3.58%
Net Profit (Loss) for the Period
-91.21%
Total assets
70.52%
Total equity
112.02%
Operating Profit Margin (ROS)
-1.11%
Net Profit Margin
-1.39%
Return on Equity (ROE)
-3.86%
Debt to Equity Ratio
-10.85%
Quick Ratio
1.01%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?